efpeglenatide (HM11260C) / Hanmi, Sanofi  >>  Phase 2
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
efpeglenatide (HM11260C) / Hanmi
NCT01452451: Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

Completed
2
72
US
HM11260C, LAPS-Exendin4, Placebo
Hanmi Pharmaceutical Company Limited
Diabetes Mellitus
06/13
 
NCT02057172 / 2013-003625-29: Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

Completed
2
254
US
HM11260C, LAPS-Exendin-4, liraglutide, Victoza, Placebo
Hanmi Pharmaceutical Company Limited
Type 2 Diabetes
10/14
12/14
NCT02075281 / 2013-004251-21: Effect of LAPS-Exendin on Body Weight in Obese Population

Completed
2
297
US
HM11260C, Placebo
Hanmi Pharmaceutical Company Limited
Obesity
01/15
02/15
NCT02081118 / 2013-004250-13: Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

Completed
2
209
US
HM11260C, LAPS-Exendin-4, Placebo
Hanmi Pharmaceutical Company Limited
Type 2 Diabetes
03/15
04/15
2010-019665-28: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SEQUENTIAL DOSE ESCALATION STUDY OF THE SAFETY, TOLERABILITY, PHARMACODYNAMICS AND PHARMACOKINETICS OF SINGLE SUBCUTANEOUS DOSES OF HM11260C IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS

Completed
2
30
Europe
HM11260C, HM11260C,
Hanmi Pharmaceutical Company Limited
type 2 diabetes mellitus
 
04/11

Download Options